Translation Control Therapeutics
See the light of Protein Translation
New approach
New technology
New drugs


We are pioneering Translation Control Therapeutics, a new class of drugs that specifically control protein translation

Translation Control Discovery Platform

Breakthrough Biology

Cloud Architecture

Proprietary Analysis

Translation Control Platform
We purified and fluorescently labeled all 48 types of human tRNA
Using FRET signals from signature tRNA pair(s) of the target protein, we visualize and monitor its translation
Using all 48 tRNA pairs together, we can monitor the cell’s complete protein translation activity
Using the signature pairs for its group of proteins, we can visualize and monitor the translation of a pathway
With multiple proprietary assays, our technology helps in identifying the molecular targets of translation modulating drugs
Multiple secondary assays use proprietary techniques to identify non-toxic compounds that specifically control the target’s translation
State of the art machine learning algorithms analyze billions of data points to identify translation modulating compounds
Proprietary image analysis algorithms run over millions of images to select images where the “translation light” has been affected
85% of known proteins have a “signature tRNA pair” that repeats with high frequency in their sequence but is relatively rare in the background human genome

With our technology we can visualize and specifically control the synthesis of target proteins, enabling a new strategy against many severe diseases

Play Video

Translation Control Lab

Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture

Anima Lab

PSM Assays


Translation Data
Plate Processing
Plate Analysis
Image Analysis
PSM Image Creation
Plate Design
PSM Design
Big Data Visualisation
Bio Data Center
Big Data Analysis
• Experiment Design
• Analysis Assessment
• Bio Data Analysis
The Protein Synthesis Monitoring assay uses labeled tRNA pairs that generate FRET signals to monitor ribosome activity in selected cellular system.
PSM assay in a selected cellular system is used to screen a small molecule library of compounds towards the identification of compounds which change the PSM signal.
Unbiased scores are generated from more than 90 features extracted from images.
Images captured by Operetta® are automatically uploaded to the Cloud using proprietary plate processing software.
QA measures are executed to eliminate outliers wells and cells and to identify false positives.
State of the art image analysis algorithms extract unique PSM and additional cellular features as a feed for the big data analysis.
All images are captured by Operetta®, and the clean, calculated, PSM images is generated automatically.
FRET controls, assay controls are located at specific wells in all screens, enabling strict QA algorithms.
PSM design is based on proprietary mathematical algorithms analyzing the relevant RNA code.
Powerful visual and analytical tools enable us to view the results online from various mathematical and biological angles
All biological data and results are kept in a customized industry standard bio data center.
The analysis utilizes proprietary biological big data algorithms designed for translation control modulators discovery with high level of statistical significance.

See the Light of Protein Translation

Product Pipeline

Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).

Assay Development
Hit Generation
Hit to lead
Collagen I - Target2 Liver Fibrosis
Collagen I - Target3 Scleroderma
RSV Viral Translation Inhibitors
C-Myc Oncology / Longevity
Huntingtin Huntington's disease

Pharma Collaborations

Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

17 Scientific Collaborations

14 Publications

News & Events

  • SACHS Associates 2018

    When: October 4th, 2018 - October 5th, 2018
    Where: Basel, Switzerland

    Anima Biotech will participate and present at the 18th Annual Biotech in Europe Forum. In Addition, Yochi Slonim, Anima Biotech co-founder & CEO, will co-chair the Platform Technologies & Novel Therapeutics Panel.
    The Sachs Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry.

    Visit the conference website »

  • Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

    When: July 23rd, 2018

    Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.

    Read the full Press Release
    Download Press Release in English »
    Download Press Release in Hebrew »

  • International tRNA Conference 2018

    When: September 23rd, 2018 - September 27th, 2018
    Where: Strasbourg, France

    Anima Biotech will participate and present at the 27th International tRNA Conference “tRNA at the crossroad”.

    This event brings together researchers from around the world studying the many aspects of tRNA biology.

    Visit the conference website »